Patent intelligence · US
US 12097183
Pharmaceutical composition for treating migraine
Pharmaceutical composition for treating migraine
Patent details — US 12097183
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 24, 2024
- Expiration
- Sep 19, 2044
- Applicant
- Tonix Medicines, Inc.
- Claims
- 6
- CPC classes
- A61K, A61K31/4045, A61K9/0019, A61K9/08
Quick answer
US 12097183 (Pharmaceutical composition for treating migraine) is held by Tonix Medicines, Inc.. Status: granted. Granted Sep 24, 2024. Expires Sep 19, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Tonix Medicines, Inc.
- Grant date
- Expiration
- Claims
- 6
- CPC classes
- A61K, A61K31/4045, A61K9/0019, A61K9/08, A61P, A61P25/06
More from Tonix Medicines, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12383733
Iontophoresis-based patch type medicine absorption device
granted -
US 12365879
Synthetic chimeric poxviruses
granted -
US 12304901
Selective ligands for tau aggregates
granted -
US 12156897
Magnesium-containing oxytocin formulations and methods of use
granted -
US 12156864
Analogs of cyclobenzaprine and amitryptilene
granted -
US 12090139
Formulations comprising triptan compounds
granted -
US 11998516
Methods and compositions for treating depression using cyclobenzaprine
granted
Frequently asked questions
What is US patent 12097183?
US 12097183 (Pharmaceutical composition for treating migraine) is held by Tonix Medicines, Inc.. Status: granted. Granted Sep 24, 2024. Expires Sep 19, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12097183?
Tonix Medicines, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 86 pharmaceutical patents for this assignee.
When does US 12097183 expire?
Our index shows an expiration date of Sep 19, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.